KATRD
LOGIN
- KATRD 2021 International Conference
-
November 7(Thu)-8(Fri), 2020 Lotte Hotel World, Seoul, Kore
Program in Detail
|
Oral Presentation 10 COPD 2 |
12:50-13:30 |
||
|---|---|---|---|
| Chair | |||
| 10:30-10:40 | OP 10-1 |
Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA Versus ICS/LABA in COPD Management: Findings from the Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
|
|
| 10:40-10:50 | OP 10-2 |
Assessment of Satisfaction with the Inhaler and Determinants of High Satisfaction in COPD Patients
|
|
| 10:50-11:00 | OP 10-3 |
Comparison of Pneumonia Incidence between LAMA and ICS/LABA in Patients with COPD : A Retrospective Cohort Study in a Real-world Setting
|
|
| 11:00-11:10 | OP 10-4 |
Comparison of Risk of Pneumonia Caused by Fluticasone Versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
|
|
| 11:10-11:20 | OP 10-5 |
Association between Inhaled Corticosteroids Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
|
|
| 11:20-11:30 | OP 10-6 |
Seasonal Variations in PM2.5 Concentrations and Clinical Impact on Chronic Obstructive Lung Disease Patients
|
|
| 11:30-11:40 | OP 10-7 |
Clinical Implication in COPD Assessment Test Score Changes among Newly Diagnosed COPD Patients Treated with Bronchodilators
|
|
| 11:40-11:50 | OP 10-8 |
Diaphragm Ultrasound is an Image Biomarker of AECOPD
|
|
| 11:50-12:00 | OP 10-9 |
Systemic Antibiotics Can Deteriorate Emphysema Associated with Exaggerated Inflammation and Autophagy
|
|
|
Oral Presentation 12 Bronchoscopy/ Diagnostics |
14:20-15:00 |
||
| Chair | |||
| 15:30-15:40 | OP 12-1 |
Diagnostic Utility of Adding Needle Aspiration (Using PeriView FLEX needle®) to Radial EBUS Transbronchial Lung Biopsy
|
|
| 15:40-15:50 | OP 12-2 |
Utility and Safety of Sole Electromagnetic Navigation Bronchoscopy Under Moderate Sedation for Lung Cancer Diagnosis
|
|
| 15:50-16:00 | OP 12-3 |
Is Bronchial Washing Cytology Helpful for the Diagnosis of Lung Cancer?
|
|
| 16:00-16:10 | OP 12-4 |
Additional Value of Metagenomic Sequencing in Diagnosis of Ventilator-associated Pneumonia
|
|
| 16:10-16:20 | OP 12-5 |
Efficacy of Hand-held Portable Ultrasound in Early Detection of Pneumothorax after Lung Biopsy
|
|
| 16:20-16:30 | OP 12-6 |
Deep Learning-based Classification of Respiratory Sounds and Its Clinical Value
|
|
| 16:30-16:40 | OP 12-7 |
Proposal of a Novel Lung Fibrosis Scoring System for Post-COVID-19 Lung Fibrosis Patients
|
|
| 16:40-16:50 | OP 12-8 |
Mutations in gyrA and gyrB among Drug Resistant Mycobacterium Tuberculosis in Korea
|
|
| 16:50-17:00 | OP 12-9 |
Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Lesions: A Systematic Review and Meta-analysis
|
|
|
Oral Presentation 13 ILD 1 |
12:50-13:30 |
||
| Chair | |||
| 10:30-10:40 | OP 13-1 |
Clinical Outcomes of Dose Modification During Pirfenidone Treatment in Patients with IPF
|
|
| 10:40-10:50 | OP 13-2 |
The Efficacy of Pirfenidone in Combined Pulmonary Fibrosis and Emphysema (CPFE)
|
|
| 10:50-11:00 | OP 13-3 |
Prevalence of and Risk Factors for Pulmonary Complications after Curative Resection in Idiopathic Pulmonary Fibrosis Patients with Early Stage Lung Cancer
|
|
| 11:00-11:10 | OP 13-4 |
Validity of Pulmonary Artery to Aorta Ratio as a Predictor of Acute Exacerbation in Advanced Idiopathic Pulmonary Fibrosis Patients
|
|
| 11:10-11:20 | OP 13-5 |
Serum Apolipoprotein A-I Predicts the Mortality in Patients with Idiopathic Pulmonary Fibrosis
|
|
| 11:20-11:30 | OP 13-6 |
Body Mass Index and Clinical Outcomes in Patients with Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study
|
|
| 11:30-11:40 | OP 13-7 |
The Analysis of the Effect of Ischemic Heart Disease on the Clinical Course of IPF
|
|
| 11:40-11:50 | OP 13-8 |
Non-tuberculous Mycobacterial Pulmonary Disease Increased the Risk of Hospitalization in Patients with Idiopathic Pulmonary Fibrosis
|
|
| 11:50-12:00 | OP 13-9 |
Comparison of the Clinical Course of Patients with Idiopathic Pulmonary Fibrosis According to Their Smoking Status
|
|
|
Oral Presentation 14 ILD 2 |
13:30-14:20 |
||
| Chair | |||
| 13:30-13:40 | OP 14-1 |
Clinical Characteristics of Familial Idiopathic Pulmonary Fibrosis Patients in Korea
|
|
| 13:40-13:50 | OP 14-2 |
Clinical Features between Cryptogenic and Secondary Organizing Pneumonia in a Single Hospital
|
|
| 13:50-14:00 | OP 14-3 |
Clinical Factors Associated with Lung Function Decline and Mortality in Rheumatoid Arthritis-related Interstitial Lung Disease
|
|
| 14:00-14:10 | OP 14-4 |
Characteristics, Mortality, and Risk Factors in Patients with Systemic Sclerosis Associated Interstitial Lung Disease
|
|
| 14:10-14:20 | OP 14-5 |
Interstitial Lung Abnormality in Health Screening Examinees: Prevalence and Progression Rate
|
|
| 14:20-14:30 | OP 14-6 |
Effects of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases by Composite Physiologic Index
|
|
| 14:30-14:40 | OP 14-7 |
Diagnostic Performance of Digital Lung Auscultation for Interstitial Lung Diseases
|
|
| 14:40-14:50 | OP 14-8 |
Imaging Signatures in Idiopathic Pulmonary Fibrosis (IS-IPF) Study from Multi-center Multidisciplinary Experiences in Interstitial Lung Disease
|
|
| 14:50-15:00 | OP 14-9 |
Interstitial Lung Abnormality Evaluated by Automated Quantification System: Prevalence and Progression Rate
|
|
|
Oral Presentation 15 ILD 3 |
14:20-15:00 |
||
| Chair | |||
| 15:30-15:40 | OP 15-1 |
Blood KL-6 Predicts Disease Progression in IPF Patients Receiving Antifibrotic Therapy
|
|
| 15:40-15:50 | OP 15-2 |
Serum Krebs von den Lungen-6 (KL-6) as a Biomarker for the Disease Progression of Idiopathic Pulmonary Fibrosis
|
|
| 15:50-16:00 | OP 15-3 |
Diagnostic Value of Serum Vascular Endothelial Growth Factor-D in Korean Patients with Lymphangioleiomyomatosis
|
|
| 16:00-16:10 | OP 15-4 |
Serum Proteomic Profiling of Rapid Disease Progression in Idiopathic Pulmonary Fibrosis
|
|
| 16:10-16:20 | OP 15-5 |
New Biomarker in Rapid Progressor of Idiopathic Pulmonary Fibrosis
|
|
| 16:20-16:30 | OP 15-6 |
Plasma Mitochondrial DNA as a Biomarker of Clinical Outcomes in Rheumatoid Arthritis-associated Interstitial Lung Disease
|
|
| 16:30-16:40 | OP 15-7 |
Exogenous Tryptophan Aggravates Experimental Lung Fibrosis Through Activation of AKT-mTORC1 Pathway
|
|
| 16:40-16:50 | OP 15-8 |
Arachidonic Acid 12-lipoxygenase (ALOX12) Promotes Pulmonary Fibrosis
|
|
| 16:50-17:00 | OP 15-9 |
Periostin is a Novel Biomarker for Chronic Lung Allograft Dysfunction after Lung Transplant
|
|
|
Oral Presentation 16 Lung Cancer 1 |
12:50-13:30 |
||
| Chair | |||
| 10:30-10:40 | OP 16-1 |
microRNA-26a-5p Regulates the Cancer stemness and Enhances the Chemosensitivity of Lung Adenocarcinoma
|
|
| 10:40-10:50 | OP 16-2 |
Heterogeneous Radiological Response to Chemotherapy is Associated with Poor Prognosis in Advanced Non-small-cell Lung Cancer
|
|
| 10:50-11:00 | OP 16-3 |
Clinical Significance of Advanced Lung Cancer Inflammation Index in Limited Disease Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
|
|
| 11:00-11:10 | OP 16-4 |
Impaired Lung Function and Lung Cancer Incidence: A Nationwide Population-based Cohort Study
|
|
| 11:10-11:20 | OP 16-5 |
Blood-based Biomarker Analysis for Predicting Efficacy of Definitive Concurrent Chemoradiotherapy and Durvalumab Consolidation in Patients with Unresectable Locally Advanced Non-small Cell Lung Cancer
|
|
| 11:20-11:30 | OP 16-6 |
Clinical Usefulness of Serum KL-6 Test for Predicting Occurrence and Assessing Severity of Treatment-related Interstitial Lung Disease in Lung Cancer: A Single Center Cohort Study
|
|
| 11:30-11:40 | OP 16-7 |
Association between Clinical Parameters and Resectability in Stage III Non-small Cell Lung Cancer
|
|
| 11:40-11:50 | OP 16-8 |
Tri-iodothyronine (T3) as a Prognostic Factor for Patients with Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
|
|
| 11:50-12:00 | OP 16-9 |
Digital Aging and Mental Health Deteriorations: Risk Mitigation in the Older People with Lung Cancer Disease in Indonesia
|
|
|
Oral Presentation 17 Lung Cancer 2 |
13:30-14:20 |
||
| Chair | |||
| 13:30-13:40 | OP 17-1 |
High Tumor Mutation Burden Predicts Unfavorable Clinical Outcomes in EGFR-mutated Lung Adenocarcinoma Treated with Targeted Therapy
|
|
| 13:40-13:50 | OP 17-2 |
GDF-15 Levels Predict Efficacy in Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors
|
|
| 13:50-14:00 | OP 17-3 |
Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-dose CT Screening
|
|
| 14:00-14:10 | OP 17-4 |
Comparison of Clinical Characteristics and Prognosis of Incidentally Detected and Screening Detected Lung Cancers
|
|
| 14:10-14:20 | OP 17-5 |
Incidence and Risk Factors for Brain Metastasis in Patients with Presumed Early-stage Lung Cancer
|
|
| 14:20-14:30 | OP 17-6 |
Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients with Lung Cancer
|
|
| 14:30-14:40 | OP 17-7 |
Clinical Factors Associated with Circulating Tumor DNA Detection in Chronic Obstructive Pulmonary Disease Patients with Lung Cancer
|
|
| 14:40-14:50 | OP 17-8 |
Semi-supervised Deep Learning Extraction for Information of Lung Cancer Staging from Unstructured Reports of PET-CT Interpretation
|
|
| 14:50-15:00 | OP 17-9 |
Machine Learning Classification of Bronchogenic Carcinoma based on Fuzzy Logic
|
|
|
Oral Presentation 18 Lung Cancer 3 |
14:20-15:00 |
||
| Chair | |||
| 15:30-15:40 | OP 18-1 |
Effects of Developed Chronic Pulmonary Aspergillosis after Lung Cancer Surgery on Mortality and Lung Function Decline
|
|
| 15:40-15:50 | OP 18-2 |
Efficacy of Local Radiotherapy or Metastasectomy in Stage IV NSCLC with Single Extrathoracic Metastasis: Evaluation of Nationwide Korean Lung Cancer Populations
|
|
| 15:50-16:00 | OP 18-3 |
Predictability of Prior Radiotherapy and Immunotherapy-related Adverse Effects for Outcomes in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy
|
|
| 16:00-16:10 | OP 18-4 |
The Role of 6-minute Walk Test and Cardiopulmonary Exercise Test in Early-stage Lung Cancer Patients with Reduced Pulmonary Function
|
|
| 16:10-16:20 | OP 18-5 |
Association of Diagnostic Lung Biopsy on the Risk of Spread Through Air Spaces (STAS) and Its Prognostic Impact in Resected Stage I Non-Small Cell Lung Cancer (NSCLC)
|
|
| 16:20-16:30 | OP 18-6 |
Comparison of Clinical Stage and Pathologic Stage in Patients with Non-small Cell Lung Cancer
|
|
| 16:30-16:40 | OP 18-7 |
Real-world Experience on the Use of Durvalumab after Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer
|
|
| 16:40-16:50 | OP 18-8 |
A Propensity-matched Real-world Data Analysis of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer
|
|
| 16:50-17:00 | OP 18-9 |
Stereotactic Body Radiation Therapy in Stage I Non-small Cell Lung Cancer Patients with Peripheral Tumors in Vietnam
|
|